



Ministry of Foreign Affairs

From California to Texas: Exploring U.S. Life Sciences & Health Innovation Hubs for Dutch Innovators

Commissioned by the Netherlands Enterprise Agency

*>> Sustainable. Agricultural. Innovative.
International.*



FROM CALIFORNIA TO TEXAS: Exploring U.S. Life Sciences & Health Innovation Hubs for Dutch Innovators

Table of Contents

Acknowledgements.....	2
About Us.....	3
Scope of This Report	4
Beyond Boston	6
Federal Initiatives	8
California	10
Florida	14
Minnesota	18
North Carolina.....	22
Texas	26
Other LSH Innovation Hubs in the United States.....	30
About the Dutch Diplomatic Network in the U.S.....	34

Acknowledgements

This report was prepared by Bas van Kruining, Junior Innovation Officer and edited by Tazrin Hossain, Senior Advisor for Innovation, Technology & Science.

The report was based on an evaluation of qualitative research methods, including a comprehensive literature review and expert interviews conducted with each innovation hub and through the Dutch diplomatic network.

Thank you to following experts who contributed insights during the development of this report:

Name	Organization
Carol Nasseh	Florida High Tech Corridor
Dave Munneke	Black Oaks Consulting
Deenadayalan Bakthavatsalan	CUBIO Innovation Hub
David Pieklik	FloridaCommerce
Gail Maderis	Antiva Biosciences
Kylle Jordan	Destination Medical Center
Mireya McKee	Innovate Carolina at UNC-Chapel Hill
Paul Hoogervorst	University of Minnesota
Rachel Page	Go Global NC

About Us


The Netherlands Innovation Network (NIN) is the science and technology arm of the Dutch diplomatic network. This global network operates in 16 countries worldwide, with offices in three locations in the United States: Washington, DC, Boston and San Francisco. NIN works to facilitate international cooperation in science and technology, by connecting Dutch startups, companies, and research institutes with opportunities abroad. The NIN also aims to support the Dutch government's international knowledge and innovation agenda.

In 2019, during an official economic mission from the Netherlands to Boston led by former Prime Minister Mark Rutte, representatives from public investment agencies, the biotech industry and other organizations convened to discuss a broad-based partnership to advance ongoing collaboration in life sciences between the Netherlands and the Commonwealth of Massachusetts. These discussions resulted in the signing of a Memorandum of Understanding (MoU) that evolved into a fully actionable Program of Cooperation (PoC) formalized in 2022. This unique transatlantic partnership in life sciences and health demonstrates a commitment to partnership and enables joint activities and collaborations to strengthen both life sciences ecosystems through the exchange of scientific knowledge, innovations and entrepreneurship and is the umbrella under which all joint activities in the sector occur. Signatories include the Massachusetts Office of International Trade and Investment, MassBio, the Massachusetts Life Sciences Center, the Termeer Foundation, the Ministry of Economic Affairs, Health~Holland, HollandBIO, and Vereniging Innovative Geneesmiddelen (VIG).

If you are interested in getting in touch with the Netherlands Innovation Network in Boston, please email your inquiry to nin@nost-boston.org or follow us on [LinkedIn](#).

Scope of This Report

While Boston, Massachusetts remains a cornerstone of the U.S. LSH sector, the Roadmap LSH USA 2024-2027 (developed in 2020-2021 through a collaboration between a vast amount of both public and private partners) identifies several other regions with promising opportunities for Dutch entrepreneurs. The Roadmap LSH USA 2024-2027 builds on ongoing initiatives and provides a structured, integrated approach to strengthening Dutch engagement in the U.S. market. By fostering coordinated cooperation between industry, knowledge institutions, the Dutch economic network in the U.S., and government bodies, it aims to reduce fragmentation and enhance strategic focus.



As a globally recognized innovation hub, the Dutch LSH sector—home to over 3,000 R&D companies, including more than 400 biopharmaceutical firms—offers significant expertise in biopharmaceuticals, medical technology, and digital health. This roadmap identifies key U.S. regions where Dutch strengths align with growing demand for advanced healthcare solutions.

This report highlights opportunities for collaboration in data infrastructure, digital health application research, and joint R&D. By identifying ‘sweet spots’ for knowledge exchange,

entrepreneurial programs, and strategic partnerships, it seeks to connect Dutch and U.S. initiatives in a way that accelerates innovation and market adoption. These regions—supported by strong academic institutions, industry partnerships, and favorable policies—provide Dutch entrepreneurs with a dynamic environment to scale their solutions and drive impactful advancements in all LSH verticals in the following innovation hubs:

California, with hubs in San Francisco, Los Angeles, and San Diego, remains a global leader in biopharmaceutical innovation, digital health, and transformative technologies such as AI-driven drug discovery and gene editing. Its world-class universities and robust infrastructure make it an attractive destination for research partnerships and commercial expansion.

Texas has emerged as a hub for biomanufacturing and telemedicine, with the Texas Medical Center being one of the largest medical complexes globally. Recent collaborations between Texas and the Netherlands highlight the potential for joint ventures and knowledge exchange.

Similarly, **Florida**, particularly Miami and Central Florida—is rapidly gaining recognition for its strengths in digital health and MedTech, fueled by a diverse patient population and international healthcare conferences.

North Carolina – particularly its Research Triangle – is an innovation powerhouse for precision medicine and R&D, strengthened by initiatives like the "Beyond the Beltway" program, which promotes collaboration between Dutch and U.S. stakeholders.

Finally, **Minnesota** – particularly Medical Alley – is globally recognized for its expertise in MedTech and manufacturing, providing a strong base for companies specializing in medical devices and diagnostics to scale their operations.

Dutch policymakers have increasingly focused on these regions, with upcoming economic missions in 2025 aiming to deepen engagement and foster new business opportunities. This report explores these priority regions in depth, offering practical strategies for Dutch entrepreneurs to successfully integrate into these ecosystems and drive sustainable growth.

Beyond Boston

Boston is at the forefront of LSH innovation, bolstered by its academic excellence, cutting-edge research, and strong public-private partnerships. [Harvard University](#) and the [Massachusetts Institute of Technology](#) (MIT) form the backbone of its ecosystem, complemented by more than \$3 billion in annual National Institute of Health (NIH) funding. This financial and institutional foundation enables Boston to consistently drive scientific breakthroughs and accelerate the commercialization of research.

The city is home to a dense concentration of life sciences companies, ranging from global industry leaders like [Thermo Fisher Scientific](#) and [Boston Scientific](#) to high-growth startups supported by the largest venture capital network in the U.S. In 2023 alone, the Boston-Cambridge area attracted \$11.2 billion in life sciences venture capital ([CBRE, 2023](#)). Combined with its advanced lab infrastructure and robust clinical trial capabilities, Boston is a top destination for cutting-edge medical innovation.

Boston's prominence in the Life Sciences and Health (LSH) sector is further reinforced by its substantial employment base and robust infrastructure. As of 2021, Massachusetts boasted over 106,000 biopharma employees, reflecting a remarkable 96.5% increase since 2008, when the Massachusetts Life Sciences Initiative was enacted ([EPM Scientific, 2024](#)).

This growth is supported by the addition of more than 21.6 million square feet of lab space in the past decade, a 117% increase, providing ample facilities for research and development ([Mass Life Sciences, 2024](#)).

To nurture innovation and support emerging enterprises, Boston offers a diverse array of incubators and accelerators ([Brandeis Innovation, 2024](#)). Notable amongst these in the LSH sector are [MassChallenge](#), a renowned accelerator supporting startups across various sectors including healthtech without taking equity, and [BioLabs](#), an international, membership based network of fully equipped, all-inclusive shared lab and office facilities for early-stage LSH startups, with three locations in Boston, Cambridge and Watertown, Massachusetts. Additionally, [LabCentral](#) offers fully equipped lab and office spaces for biotech startups, fostering a collaborative environment for scientific advancement. These resources, combined with Boston's extensive venture capital network, create a fertile ecosystem for life sciences innovation.


However, Boston's unparalleled success has also introduced significant challenges, including heightened competition, rising operational costs, and limited availability of real estate. These constraints have accelerated the expansion of other key innovation hubs. For Dutch innovators, these emerging innovation hubs offer alternative pathways, with rich talent pools, specialized industry expertise, and potentially lower barriers to entry compared to Boston's saturated market.

Boston in 5

1. Massachusetts' biopharma workforce grew 96.5% since 2008, supported by strong R&D investment.
2. Boston attracted \$11.2 billion in LSH venture capital in 2023.
3. Over \$3 billion in NIH funding supports Boston's top research institutions annually.
4. 30+ biotech incubators and accelerators drive Boston's thriving startup ecosystem.
5. 50+ universities and colleges are based in the Greater Boston area, including top institutions like Harvard and MIT.

Federal Initiatives

At the time of writing this report, a change in U.S. presidential administration – marked by the beginning of the Trump 2.0 presidency – is expected to influence several of the key policies and federal initiatives related to LSH, healthcare innovation and international collaboration, potentially affecting the strategic landscape for Dutch entrepreneurs.



Source: [University of Notre Dame, Wireless Institute](#)

The [CHIPS and Science Act](#) provides funding for research in advanced computing applications for genomics, diagnostics, and drug discovery. [The Inflation Reduction Act](#) (IRA) incentivizes sustainable healthcare solutions, including energy-efficient medical devices and cost-saving digital health platforms.

[The America COMPETES Act](#) promotes R&D partnerships in precision medicine and biopharmaceutical technologies, while [ARPA-H](#) supports high-risk, high-reward projects in areas

such as gene therapy, oncology, and advanced medical technologies. [The Tech Hubs Program](#) is specifically designed to accelerate biotech innovation in states like North Carolina, Texas, and California, and the International Entrepreneur Rule offers Dutch founders a structured pathway to establish and grow startups in the U.S.

The [America First Investment Policy](#), introduced by President Trump on February 21, 2025, aims to enhance U.S. national and economic security by regulating foreign investments. This policy seeks to encourage investments from allied nations through expedited approval processes, while imposing stricter limitations on investments from adversarial countries to safeguard critical American technologies and infrastructure. As the policy is newly established, its implementation is forthcoming. Dutch entrepreneurs in the life sciences and biotechnology sectors should be aware of this development, as it may influence investment opportunities and regulatory considerations in the U.S.

Additionally, while the [National Institutes of Health \(NIH\)](#) is seeing significant changes under the Trump Administration 2.0, it remains a source of funding for biomedical research, offering grants and collaboration opportunities in transformative areas. These areas include hugely transformative areas such as cell and gene therapy, oncology, and rare diseases.

California

California is a leading U.S. hub for biotech and life sciences, where advanced technologies such as AI, computational biology, and digital health converge. The state combines world-class research institutions, a dynamic startup culture, and a strong venture capital ecosystem, making it a global hotspot for healthcare innovation. San Diego, Los Angeles, and the Bay Area form the core of the biotech sector, each with a unique specialization: San Diego excels in genomics and precision medicine, Los Angeles in medical technology and digital health solutions, and the Bay Area in AI-driven biotechnology and regenerative medicine. In addition to its innovation capacity, California benefits from a robust funding landscape, where both biotech investors and tech giants like Google and NVIDIA play a major role. With strong academic-industry partnerships, extensive incubator and accelerator programs, and a diverse range of funding opportunities, California offers a complete infrastructure for startups and established companies to develop and scale groundbreaking innovations.

Ecosystem highlights

California's biotech ecosystem is shaped by deep AI integration, driving breakthroughs in drug discovery, genomics, and digital therapeutics. Top universities, including [UCSF](#), [Stanford](#), [UC San Diego](#), and [Caltech](#), collaborate with industry leaders to translate cutting-edge research into commercial solutions. AI-driven drug development is rapidly transforming the pharmaceutical industry, with biotech firms leveraging machine learning to optimize clinical trials, predict drug interactions, and accelerate regulatory approvals. Computational biology is playing an increasingly vital role in genomics, with companies utilizing AI-powered platforms to analyze vast datasets, identify genetic markers, and personalize treatment strategies.

Beyond drug discovery, collaborations across biotech, AI, and engineering fuel advancements in synthetic biology, bioinformatics, and medical imaging. AI-powered platforms optimize genetic engineering, refine diagnostics, and enable precision medicine. The fusion of life sciences and

Ecosystem in Numbers

> 50 incubators and accelerators supporting startups and R&D commercialization across the state (CLA)

Top 5

San Diego ranked among the top five global biotech hubs for startup innovation (EY)

Top 3

California's integration of AI in healthcare ranks among the best worldwide (CLA)

technology makes California a unique environment for biotech startups and established firms alike, positioning it as the global leader in AI-driven health innovation.

Funding

California's biotech sector benefits from the most developed venture capital ecosystem in the U.S., attracting over \$5 billion in life sciences investment in 2023 ([CBRE, 2024](#)). Its unique integration with the AI and tech sectors has positioned the state as a global leader in AI-driven drug discovery, computational biology, and digital health. This convergence has drawn interest from both traditional biotech investors, such as [ARCH Venture Partners](#), [Third Rock Ventures](#), and [Versant Ventures](#), and Silicon Valley tech-focused firms like [Google Ventures](#), [A16Z Bio](#), and [First Spark Ventures](#).

Unlike Boston, where funding models focus on long-term clinical development, California offers more diverse investment pathways. AI-powered biotech startups often secure early backing from tech-oriented investors before scaling through institutional rounds. Many benefits from seed-stage funding through incubators and accelerators, allowing them to develop proof-of-concept models before attracting large-scale venture financing. Corporate venture capital plays a major role, with pharmaceutical and technology giants actively acquiring and funding biotech startups. Johnson & Johnson, Merck, and Bristol-Myers Squibb have made strategic investments in California-based companies, while Google, NVIDIA, and Apple have fueled innovation in AI-powered diagnostics, digital therapeutics, and biosensors. This cross-sector funding landscape gives startups access to both biotech and deep-tech capital, a key differentiator for the state's ecosystem.

Public funding is also a significant driver. The NIH awarded \$1.1 billion in research grants to San Diego alone in 2023, helping early-stage companies fund preclinical research and clinical trials. State-backed initiatives, such as [California's Institute for Regenerative Medicine](#) (CIRM), provide non-dilutive funding to biotech startups focused on cell and gene therapy. Despite economic fluctuations, California remains the top biotech investment hub, with a strong pipeline of Series A and B funding rounds. The region continues to attract M&A activity, with large pharmaceutical firms acquiring emerging startups to strengthen their drug pipelines. This dynamic ecosystem, fueled by private investment, corporate partnerships, and government funding, ensures that biotech firms at every stage – from seed funding to IPO – can access the resources they need to scale.

Talent

California's biotech sector benefits from an unmatched talent pool that blends expertise in biotechnology, AI, and computational biology. The state's universities produce a steady pipeline of top-tier graduates, while its proximity to Silicon Valley ensures a continuous influx of AI engineers and data scientists into the life sciences sector. This integration has fueled the rise of AI-powered biotech startups and companies, using deep learning for drug discovery, biomarker detection, and real-time diagnostics. Unlike other life sciences hubs, California benefits from direct engagement with global technology leaders who actively invest in AI-driven healthcare solutions. This dynamic collaboration has made the state a key driver of the next wave of biotech breakthroughs, where AI is seamlessly embedded into life sciences R&D.

Access to the ecosystem

California provides one of the most comprehensive landing infrastructures for biotech startups, offering industry networks, incubators, accelerators, and commercialization platforms that facilitate market entry and scaling. [Biocom California](#), the largest life sciences trade association in the state, serves as a connector between startups, investors, and corporate partners. It provides policy advocacy, business development support, and investor matchmaking, ensuring that biotech firms can access funding and commercialization opportunities. [California Life Sciences](#) (CLSA) plays a crucial role, particularly for international biotech companies entering the U.S. market. Through soft-landing programs and venture capital matchmaking, CLSA helps startups navigate regulations, secure funding, and build academic-industry partnerships. A robust incubator and accelerator network supports startups with lab space, mentorship, and funding access. [JLABS](#), in San Diego and the Bay Area, offers flexible lab space and commercial guidance, while [MBC BioLabs](#) focuses on AI-driven biotech ventures, helping startups integrate machine learning into drug discovery. Stanford's [StartX](#) and [UCSF's Rosenman Institute](#) accelerate digital health and MedTech companies, ensuring access to Silicon Valley's investor ecosystem.

Incubators & Accelerators

JLABS (San Diego & Bay Area)

A premier life sciences incubator offering lab space, mentorship, and commercialization support for biotech startups.

MBC BioLabs (San Francisco & San Carlos)

A leading incubator for AI-driven biotech companies, providing lab access and investor connections.

BioLabs LA at The Lundquist Institute (Los Angeles)

A flexible co-working lab space for early-stage biotech startups, offering mentorship and investor access

For biotech startups focused on cutting-edge therapeutics, the [Termeer Foundation](#) provides mentorship and leadership development, connecting early-stage founders with biotech executives and offering guidance on funding and regulatory pathways. San Diego's startup culture and university-industry links support genomics and precision medicine. Los Angeles fosters AI-driven healthcare, synthetic biology, and medical imaging. The Bay Area leads AI-biotech integration, benefiting from tech investors and research institutions. The state's real estate infrastructure also plays a vital role. Torrey Pines in San Diego, South San Francisco, and Culver City in the LA Metropolitan area host biotech campuses. These hubs provide access to research facilities, wet lab space, and industry networks, ensuring startups can transition from R&D to commercialization. With integrated industry networks, commercialization platforms, and access to cross-sector innovation, California remains a top launchpad for biotech startups scaling in the U.S. market.

CALIFORNIA IN 5

1. California leads globally in AI-driven biotech, medtech & computational biology innovation
2. Major biotech hubs in San Diego, Los Angeles and the Bay Area.
3. Top research universities drive cutting-edge biotech, genomics and AI-health advancements.
4. Silicon Valley tech giants invest heavily in AI-driven healthcare innovation.
5. NIH & state funding drive research in cell therapy and medtech application.

Florida

Florida has positioned itself as a rapidly growing innovation hub for life sciences and biotechnology, driven by world-class research institutions, a dynamic entrepreneurial ecosystem, and strong industry-government collaboration. The state's strategic location, business-friendly policies, and investment in cutting-edge research have made it an increasingly attractive destination for biotech and MedTech companies looking to expand into the U.S. market. With major clusters in Miami, Tampa, and Orlando, Florida offers a robust environment for research, commercialization, and workforce development in life sciences.

Ecosystem highlights

Florida has emerged as a dynamic hub for life sciences and health innovation, characterized by a strong biotechnology sector, cutting-edge research institutions, and a business-friendly environment. The state is home to over 8,600 life sciences establishments, employing more than 150,000 professionals across biotech, pharmaceuticals, and medical device manufacturing. With \$64.3 billion in economic output from the biopharmaceutical sector in 2023, Florida has positioned itself as an attractive location for life sciences investment and expansion ([CBRE, 2024](#)).

Central Florida has seen rapid growth in digital health, medical simulations, and biomedical research, supported by three of the country's largest research institutions like the [University of Florida](#) (UF), [University of South Florida](#) (USF), and [University of Central Florida](#) (UCF). [The Lake Nona Medical City in Orlando](#) serves as an innovation hub integrating healthcare research, clinical trials, and commercialization, encompassing a 650-acre health and life sciences park that includes renowned institutions such as the [University of Central Florida's Health Sciences Campus](#), [Nemours Children's Hospital](#), [Orlando Veterans Affairs Medical Center](#), [University of Florida Research & Academic Center](#), [GuideWell Innovation Center](#), and [UCF Lake Nona Medical Center](#). Additionally, Florida's emerging expertise in semiconductor applications for healthcare, AI-driven medical research, and space-based biological testing underscores its growing status as a strong R&D hub.

Funding

Ecosystem in Numbers

4th

Biggest Biotech R&D Infrastructure in the USA (BLS)

\$1.5 Billion

Spent in Life Sciences R&D by Florida Universities (NCSES)

2nd

Largest industry in MedTech & Pharmaceutical Manufacturing in the USA (BLS)

Florida's funding ecosystem supports a mix of startups, growth-stage firms, and established biotech leaders. The state attracts substantial National Institutes of Health (NIH) funding, totaling \$784 million in FY 2021, along with investments from venture capital and private equity sources. The [Florida High Tech Corridor Matching Grants Research Program](#) facilitates industry-academia partnerships, while [BioFlorida](#) connects startups with investors and provides advocacy for state-level incentives. BioFlorida serves as the trade association representing the life sciences and healthcare sector in Florida, focusing on biotechnology, pharmaceuticals, and medical technology. [Tampa Bay Wave's HealthTech | X Accelerator](#) and the GuideWell Innovation Center offer targeted funding opportunities for life sciences ventures.

Although most venture capital is concentrated in Miami, there is growing support for diversifying funding flows. Programs like [the Federal & State Technology Partnership \(FAST\)](#) assist innovators in securing high-risk R&D grants, while incubators like [Sid Martin Biotech](#) in Gainesville provide essential support to early-stage ventures. Florida's R&D tax incentives on equipment and corporate tax credits further enhance the financial viability of biotech expansion in the state.

Talent

Florida's life sciences sector is supported by a deep and growing talent pool, with over 20,000 graduates annually in biomedical, health sciences, and biotech fields. The state hosts some of the country's largest research universities, including UF, USF, and UCF, which offer specialized programs in biomedical engineering, pharmaceutical sciences, and digital health. Additionally, Florida is home to one of the

Incubators & Accelerators

Sid Martin Biotech

A top biotech incubator in Gainesville, offering strong industry-academia connections and state-of-the-art lab facilities.

GuideWell Innovation Center

Focused on digital health and MedTech startups in Orlando, providing tailored support, mentorship, and funding

USF CONNECT

A leading incubator in Tampa, offering a broad network, funding opportunities and support for life sciences companies.

largest medical device workforces in the U.S., with expertise spanning biopharmaceuticals, medical simulations, and regenerative medicine. The [Cenfluence](#) clustering initiative, established by the Orange County Government and the Florida High Tech Corridor and backed by state funding, fosters cross-sector collaboration and workforce development, ensuring that biotech companies can find the skilled talent needed to drive innovation. Additionally, institutions such as [Valencia College](#) provide fast-track training programs for computational scientists and biotech technicians, helping meet the industry's increasing demand for specialized skills.

Access to the ecosystem

Florida's robust innovation infrastructure supports both startups and established businesses, as well as organizations such as [SelectFlorida](#), who help entrepreneurs in their move to the US. Facilities such as the GuideWell Innovation Center provide state-of-the-art lab spaces for life sciences startups, while Lake Nona Medical City fosters advancements in healthcare research, clinical trials, and commercialization. The state also excels in MedTech commercialization through resources like the Florida High Tech Corridor, which connects entrepreneurs with industry leaders, funding sources, and research institutions to accelerate product development. Additionally, Florida's major international airports—Miami, Orlando, and Tampa—ensure seamless international connectivity for businesses looking to expand into the U.S. market.

Entrepreneurs can leverage programs like UCF's Soft-Landing Program and USF CONNECT, which provide mentorship, networking opportunities, and access to incubators that facilitate business growth. Industry organizations such as BioFlorida offer essential advocacy, funding connections, and collaborative platforms that help startups navigate the complex U.S. healthcare and biotech landscape. The state offers a variety of incubators and accelerators that facilitate commercialization, networking, and business development. Key resources include Lake Nona Medical City, which integrates research hospitals, startups, and corporations. Programs such as Launch Florida foster connections between entrepreneurs, investors, and academic partners, while the GuideWell Innovation Center serves as a dedicated ecosystem for biotech startups focused on digital health and medical advancements. Additionally, Florida's major international airports – Miami, Orlando, and Tampa – ensure connectivity for global business expansion, with direct flights to Amsterdam Schiphol.

FLORIDA IN 5

1. 50+ incubators and accelerators supporting startups.
2. Strategic location with trade access to Latin America, Europe and the rest of the United States.
3. No state income tax and performance-based initiatives offered.
4. Expansion of precision medicine and genomics research initiatives.
5. Major semiconductor R&D efforts connected to biomedical applications.

Minnesota

Minnesota, often called "Medical Alley," is one of the leading health technology hubs in the world. The state has built its reputation on excellence in medical devices, digital health, and biotechnology, serving as the headquarters for industry giants like Medtronic, Boston Scientific, 3M, and the Mayo Clinic. Its collaborative business culture, strong regulatory expertise, and cutting-edge research infrastructure make Minnesota an appealing destination for Dutch entrepreneurs seeking to expand into the U.S LSH & BioTech market. With a deep legacy in cardiovascular innovation, Minnesota has evolved into a comprehensive ecosystem which has become a world leader in Medical Devices/MedTech. Besides, the field of health IT, and biopharmaceutical advancements, provides an ecosystem with both startups and established companies with access to world-class research institutions, funding opportunities, and specialized talent pools.

Ecosystem highlights

Minnesota's leadership in MedTech stems from a legacy of innovation dating back to the 1950s, when the [University of Minnesota](#) pioneered the first battery-operated pacemaker. Today, the state is home to over 7,400 life sciences companies, employing more than 32,000 professionals in medical device manufacturing, making it the second-largest MedTech workforce in the U.S ([CBRE, 2024](#)). The state's R&D ecosystem is bolstered by major institutions such as the [Mayo Clinic](#) and the University of Minnesota, which lead in the development of implantable devices, surgical robotics, and AI-powered diagnostics. The region is known for its high concentration of medical technology patents, with more than 30% of FDA-approved medical devices originating from companies in Minnesota. The Mayo Clinic's \$5.6 billion [Destination Medical Center initiative](#) is transforming Rochester into a global hub for personalized medicine and healthcare innovation. Additionally, [Minnesota's robust Clinical Research Organization](#) (CRO) network supports clinical trials, regulatory compliance, and product development. Minnesota's strengths are further reinforced by its extensive supplier network, experienced workforce, and advanced prototyping facilities that accelerate commercialization of innovative healthcare solutions.

Ecosystem in Numbers

6.5 months

Minnesota companies secure approvals 6.5 months faster than the U.S. average

\$5.6 billion


Investment into Rochester under Destination Medical Center, trying to form a global HC Innovation Hub (DMC.MN)

2nd

Largest medtech workforce in the U.S., with 32,000+ people employed in the sector (CBRE)

Funding

Minnesota’s funding landscape, while primarily driven by corporate R&D, offers significant support for startups and entrepreneurs. Minnesota’s venture capital ecosystem is smaller than



Source: GlobalData, CBRE Research,

2024. Note: 2024 YTD as of 7.3.2024

those of Boston or the Bay Area, but its strong angel investment network provides alternative funding avenues. In 2023 alone, the state secured \$1.9 billion in grants and venture capital funding. The [Minnesota Investment Fund](#) provides grants of up to \$2 million, while a 20% tax credit incentivizes private investment in early-stage companies. The [Medical Alley](#)

[Association](#) plays a crucial role in connecting businesses with venture capital and other funding sources, facilitating financial support for innovative ventures. Despite funding challenges, Minnesota’s cost-effective operational environment and corporate networks offer viable growth pathways for startups, particularly through strategic partnerships and acquisitions. Additional public funding mechanisms, including federal grants and state-level innovation programs, further bolster the financial ecosystem, ensuring that early-stage and scaling businesses have access to the resources necessary for growth. The [Mayo Clinic Ventures initiative](#), alongside university-led investment programs, actively fosters innovation by funding breakthrough research and providing commercialization pathways for startups in the MedTech and Biotech sectors.

Talent

The Minneapolis-St. Paul metro area hosts a highly skilled workforce supported by top-tier academic institutions, including the University of Minnesota, known for its biomedical engineering and research programs (CBRE, 2024). State-led initiatives and specialized technical training programs enhance Minnesota’s talent pipeline, contributing to the MedTech workforce, which represents 16% of the U.S. total. Minnesota excels in manufacturing Class III medical devices, regulatory compliance, and AI-driven healthcare innovations. Despite challenges in attracting new talent due to its geographic location, the state offers technical education programs that expose students to high-tech manufacturing and medical device engineering, strengthening the future workforce and ensuring a steady supply of skilled professionals. In addition to its robust educational infrastructure, Minnesota has the highest concentration of medical technology workers in the U.S., making it a magnet for top talent in the industry. The region also benefits from a collaborative culture that fosters knowledge exchange and cross-disciplinary partnerships, further enhancing workforce capabilities. Recent investments in workforce development, including targeted training programs in AI-assisted diagnostics, surgical robotics, and advanced biomaterials, are expanding Minnesota’s capabilities in cutting-edge MedTech and life sciences fields.

Access to the ecosystem

Incubators & Accelerators

Medical Alley Association

Connects startups with corporate partners, investors, and regulatory experts.

Mayo Clinic Innovation Exchange

Provides startups with access to Mayo Clinic’s expertise, mentorship, and resources to accelerate healthcare innovation.

Launch Minnesota

Provides mentorship, networking, and business development support for early-stage companies.

Minnesota's well-developed innovation infrastructure supports both startups and established businesses. The state's incubator ecosystem includes facilities such as [University Enterprise Laboratories](#) (UEL), as well as the [AI-focused incubator at the Mayo Clinic](#). The Earl E. Bakken Medical Devices Center at the University of Minnesota plays a pivotal role in supporting innovation, prototyping, and product development. The Minneapolis-St. Paul International Airport, rated one of the best in the U.S., provides offers a direct flight to Amsterdam Schiphol, providing great connectivity to the Netherlands. Entrepreneurs can leverage programs such as [Launch Minnesota](#) and the Medical Alley Association for mentorship, networking, and business development support. These initiatives facilitate market entry and collaboration opportunities within the ecosystem, offering startups a strong foundation to scale operations and commercialize breakthrough technologies. Minnesota's strength in facilitating market entry is also supported by its strong track record in medical device commercialization, with FDA clearances occurring 26% faster than the U.S. average. The state's extensive network of accelerators and regulatory consultants enables companies to navigate market entry and scale efficiently, while government incentives and public-private partnerships provide additional support to innovative ventures. The presence of testing and validation centers for AI-driven healthcare solutions, neuromodulation devices, and remote monitoring technologies further enhances Minnesota's role as a hub for MedTech innovation.

MINNESOTA IN 5

1. Startups benefit from access to world-class research institutions.
2. Relatively cheap costs of living, as well as a high standard of living.
3. Minnesota supports 7,400+ medtech companies.
4. Home to Mayo Clinic, the world's top ranked hospital.
5. Home to a specialized talent pool with the proximity of world-class R&D.

North Carolina

North Carolina has positioned itself as one of the most prominent innovation hubs for life sciences and biotechnology in the United States. Anchored by Research Triangle Park (RTP), the largest research park in the country, North Carolina offers unparalleled access to cutting-edge research, world-class academic institutions, and a thriving entrepreneurial ecosystem. RTP, spanning over 7,000 acres, houses more than 300 companies, including industry leaders like Novo Nordisk, GlaxoSmithKline, and BASF, alongside a growing number of innovative startups. This dynamic environment, combined with strong industry-government collaboration and business-friendly policies, makes North Carolina an increasingly attractive destination for biotech and MedTech companies looking to expand into the U.S. market. With major clusters in Raleigh, Durham, and Chapel Hill, North Carolina provides a robust framework for research, commercialization, and workforce development in life sciences.

Ecosystem highlights

North Carolina has emerged as a dynamic hub for life sciences and health innovation, characterized by a strong biotechnology sector, cutting-edge research institutions, and a business-friendly environment. The state is home to over 830 life sciences companies, employing more than 75,000 professionals across biotech, pharmaceuticals, and medical device manufacturing ([CBRE, 2024](#)). Research Triangle Park is the epicenter of this ecosystem, fostering collaboration between major corporations, academic institutions, and startups, ensuring a continuous pipeline of scientific discovery and commercialization.

The state is recognized for its leadership in cell & gene therapy, precision medicine, and biomanufacturing. Institutions such as the [Wake Forest Institute for Regenerative Medicine \(WFIRM\)](#) are at the forefront of regenerative medicine research, pioneering advancements in tissue engineering. North Carolina also benefits from a collaborative innovation ecosystem, with initiatives like [Innovate Carolina](#) supporting tech commercialization and startup growth through funding, mentorship, and networking opportunities.

Funding

Ecosystem in Numbers

4th

in the U.S. for research testing and medical labs within LSH/biotech

\$4 billion


Annual investments made into the Life Sciences R&D sector (Brookings)

Top 3

State for NIH funding, securing federal research grants for biotech innovation

North Carolina’s funding ecosystem supports a mix of startups, growth-stage firms, and established biotech leaders. The state attracts significant National Institutes of Health (NIH) funding, reinforcing its status as a leader in biomedical and biotech research. The [North Carolina Biotechnology Center](#) (NCBiotech) plays a pivotal role in fostering innovation, offering grants, venture capital connections, and partnerships. Every dollar granted by NCBiotech generates an estimated \$73 in follow-on investment, totaling more than \$4.9 billion in leveraged capital.

NCInnovation operates four regional innovation networks anchored by “hub” universities:



Source: [NCInnovation, June 2024](#)

Venture capital interest in North Carolina is rising, particularly in fields like gene therapy, biomanufacturing, and AI-driven healthcare solutions. NC Innovation, housed at RTI International, supports the commercialization of academic research, ensuring that promising discoveries reach the market. The state's major universities – [UNC-Chapel Hill](#), [NC State](#), and [Duke](#) – contribute immensely to startup incubation and tech transfer programs. Experts state that the infrastructure is already there and ready to act on the continuing rise in investments.

Talent

North Carolina's life sciences sector is supported by a deep and growing talent pool, with top-tier universities producing a steady pipeline of skilled graduates. Duke University, UNC-Chapel Hill, and NC State are renowned for their research programs in biotechnology, biomedical engineering, and pharmaceutical sciences. RTP's research institutions and corporate presence drive workforce demand, ensuring continual growth in specialized biotech expertise.

The state also excels in workforce development, with programs like the [Biotechnology and Life Science Workforce Initiative](#) ensuring that industry needs align with academic training. Research Triangle-based organizations facilitate connections between academia and industry, enabling seamless transitions from education to employment. Additionally, the state offers specialized incubator programs to support early-stage biotech entrepreneurs, connecting them with industry mentors and investors. Workforce development initiatives are increasingly incorporating AI, digital health training, and bioinformatics, ensuring North Carolina's talent pool remains ahead of industry trends. The presence of large-scale training facilities and partnerships with global health institutions strengthens the sector's ability to attract and retain top talent.

Access to the ecosystem

Incubators & Accelerators

NCBiotech Center

Provides funding, lab space, and mentorship to bridge early-stage research with commercialization, supporting startups with investment and business development.

Innovate Carolina

Supports research commercialization by linking university initiatives with venture capital and industry leaders to bring innovations to market.

First Flight VC

Incubates early-stage science and tech startups with lab space, commercialization support, and investor connections.

North Carolina's robust innovation infrastructure supports both startups and established businesses. Research Triangle Park serves as a magnet for biotech firms, offering state-of-the-art facilities, incubators, and accelerator programs. The park's environment fosters collaboration between startups, established industry players, and research institutions, ensuring an ongoing exchange of knowledge and resources.

NCBiotech's life sciences hubs and [BioLabs Durham](#) offer laboratory space, mentorship, and business development support to emerging biotech companies. [The Innovation Quarter](#) in Winston-Salem serves as a leading center for regenerative medicine and biotech entrepreneurship, while [The Frontier](#) at RTP provides flexible, affordable workspace for early-stage startups. Additionally, Raleigh-Durham International Airport ensures global connectivity, making North Carolina a strategic hub for international biotech and MedTech companies looking to enter the U.S. market.

Beyond these established hubs, North Carolina offers unique regional advantages that enhance its accessibility for biotech firms. The state's global engagement is reinforced by organizations like [Go Global NC](#), which connects international businesses to North Carolina's innovation ecosystem. Public-private collaborations streamline regulatory pathways for biotech products, ensuring a smooth transition from R&D to commercialization. Meanwhile, North Carolina's strong healthcare infrastructure, including major hospitals and research institutions, provides immediate access to clinical trial networks, facilitating faster product development and market entry for innovative biotech solutions.

NORTH CAROLINA IN 5

1. Research Triangle Park hosts 300+ companies, driving innovation and industry growth.
2. One of the highest concentrations in biotech-related fields.
3. Lowest corporate tax rate, set for elimination by 2030.
4. Over \$4 billion in annual biotech R&D funding
5. A strong state in C&G therapy, biologics and advanced manufacturing.

Texas

Texas has established itself as a major player in the U.S. life sciences and health innovation sector. With leading cities such as Houston, Dallas-Fort Worth, Austin, and San Antonio, the state provides an expansive and collaborative environment for MedTech and Digital Health enterprises, as well as BioTech. Texas boasts a strong research and development ecosystem, featuring the world-renowned Texas Medical Center (TMC) in Houston, as well as a flourishing biomanufacturing and digital health industry. The state's strategic initiatives, including public-private partnerships and workforce development programs, make it a compelling destination for Dutch entrepreneurs exploring opportunities in the U.S. market.

Ecosystem highlights

Texas is home to over 6,100 MedTech-related firms employing more than 105,000 professionals ([CBRE, 2024](#)). The state ranks second nationally in clinical trials, with over 33,000 studies conducted since 2015, demonstrating its robust capacity for medical innovation. The [Texas Medical Center](#) (TMC), spanning five square miles, is the world's largest medical complex, with more than sixty institutions serving over ten million patients annually. Within TMC, facilities such as [JLABS@TMC](#) and the [Cell Therapy Manufacturing Center](#) enable startups to accelerate research and commercialization efforts. [Houston Methodist](#) is a pivotal player in the ecosystem, with extensive research in cardiovascular technologies, robotics-assisted surgery, and digital health applications. The [BioBridge](#) between the Netherlands and the U.S. facilitates collaboration between Dutch biotech companies and Texan research institutions, further strengthening transatlantic innovation. Dallas and Austin are emerging as key MedTech and health IT hubs, with [Pegasus Park](#) in Dallas housing a concentration of startups focused on cell therapy, AI-driven diagnostics, and regenerative medicine. San Antonio, home to the [Texas Biomedical Research Institute](#), is a leader in infectious disease research and vaccine development. The [TMC3 campus](#), a \$1.5 billion collaborative project, is rapidly expanding Houston's role in precision medicine and therapeutic discovery. Additionally, Texas' strength in medical manufacturing supports advancements in AI-driven diagnostics and personalized care solutions.

Ecosystem in Numbers

2nd

Texas ranks second in the U.S. for clinical trials

\$1.5 billion

TMC3 has been working ambitious programs since 2015, investing \$1.5B in an LSH innovation hub

\$3 billion

CPRIT has already invested \$3B+ in cancer research and oncological innovation

Funding

Texas' funding landscape offers a mix of private investment, state-led initiatives, and federal support. [The Cancer Prevention and Research Institute of Texas \(CPRIT\)](#) has allocated \$3 billion to oncology research, positioning the state as a leader in cancer treatment innovation. [The Texas Enterprise Fund](#) and the [Governor's University Research Initiative \(GURI\)](#) attract top researchers and industry investments. Startups benefit from access to federal [Small Business Innovation Research \(SBIR\) and Small Business Technology Transfer \(STTR\) grants](#), alongside venture capital networks in Pegasus Park and the TMC Innovation ecosystem.

Additional funding sources include the [Texas Emerging Technology Fund](#), which supports early-stage MedTech and Digital health innovation and commercialization, and the [Texas Life Science Foundation \(TLSF\)](#), which fosters nonprofit initiatives to advance the industry. The [University of Texas at Austin](#) and [Texas A&M University](#) offer competitive research grants for biotechnology and biomedical engineering, helping startups transition from concept to market. San Antonio's [BioMedSA](#) provides grant opportunities and investment connections for life sciences ventures, while [the Texas Academy of Science](#) supports academic research in biosciences.

Texas' cost-effectiveness also enhances its appeal, with lower operational costs compared to other major biotech hubs such as Boston and San Francisco. Despite a growing venture capital scene, there is a recognized need for increased investment in early-stage biotech companies, which the BioBridge and cross-border funding initiatives aim to address. Finally, the [TMC Venture Fund](#) has built a solid position in the LSH innovation space in Texas, with over 50 million in funding spanning Digital Health, Medical Devices and Therapeutics. These diverse funding sources ensure a supportive environment for R&D and commercialization in Texas' rapidly expanding life sciences ecosystem.

Talent

Texas produces over 18,000 life sciences graduates annually, with seven of the nation's top 125 medical schools, including [Baylor College of Medicine](#) and [UT Southwestern Medical Center](#). The state leads in health sciences and biomedical engineering doctorates, ensuring a steady pipeline of professionals for the biotech industry. Workforce development initiatives, such as [InnovATEBIO](#), align education with industry needs, while partnerships with technical schools expand access to MedTech training.

Houston's life sciences workforce is bolstered by a diverse patient population and strong academic partnerships. TMC hosts more than 120,000 healthcare employees within a three-mile radius, providing an unparalleled concentration of expertise. Research institutions work closely with regulatory agencies, streamlining the path from innovation to commercialization. Workforce programs in Texas also emphasize emerging fields such as AI-driven healthcare, surgical robotics, and regenerative medicine, creating specialized talent pools that cater to the latest industry advancements. The state's ability to retain graduates through strong industry-academia partnerships enhances the stability and sustainability of its life sciences workforce.

Access to the ecosystem

Texas offers an extensive life sciences infrastructure, making it highly accessible for both domestic and international companies. The TMC Innovation Institute and JLABS@TMC provide wet lab spaces, mentorship programs, and access to clinical trial networks, streamlining the transition from R&D to market-ready products. [VelocityTX](#) in San Antonio and Launch Texas focus on funding and commercialization pathways for emerging biotech ventures.

Houston's growing life sciences real estate footprint includes Helix Park, Levit Green, and [McCord's Generation Park](#), all designed to foster collaborative research environments. Houston Methodist's expansion into Helix Park further cements the city's leadership in medical technology. Additionally, Texas benefits from a well-connected logistics network, with

Incubators & Accelerators

TMC Innovation Institute (Houston)

Provides startups with access to clinical networks, investors, and R&D infrastructure within the Texas Medical Center.

BioBridge Global (San Antonio)

Supports biomanufacturing and cell and gene therapy companies with product development and clinical validation.

JLABS (Houston @ TMC)

A premier life sciences incubator offering lab space, mentorship, and commercialization support for biotech startups.

international airports in Houston, Dallas, and Austin, ensuring global accessibility for biotech firms looking to enter the U.S. market. The state's investments in biomanufacturing and advanced logistics, including cold-chain distribution for biologics and gene therapies, make it an increasingly attractive hub for pharmaceutical and MedTech companies looking to scale their operations.

TEXAS IN 5

1. Texas Medical Center is the largest medical center in the world, serving 10 million people annually.
2. CPRIT has invested \$3 billion in cancer research and innovation.
3. Texas' tax incentives make it an affordable biotech hub.
4. Houston's expanding lab space fosters biotech commercialization and innovation.
5. Houston's expanding lab space fosters commercialization and innovation.

Other LSH Innovation Hubs in the United States

This section of the report will briefly summarize other cities that have become emerging hubs for LSH innovation in the United States. While these cities are emerging as notable hubs in the U.S. life sciences and health innovation sector, they were not expanded upon in detail in this report to maintain focus on the most strategic opportunities for Dutch entrepreneurs. The selected regions – California, Florida, Minnesota, North Carolina and Texas – are more advanced and internationally integrated ecosystems, aligning closely with the innovation priorities of Dutch companies. However, the additional hubs mentioned here present valuable secondary opportunities for collaboration and market entry, especially as these regions continue to grow and diversify their life sciences sectors. Dutch entrepreneurs should monitor these emerging markets as potential areas for future partnerships and innovation-driven expansion.

Atlanta (GA)

Atlanta is rapidly emerging as a hub for life sciences innovation, driven by cutting-edge research in biopharmaceuticals, medical technology, and digital health. Institutions like [Emory University](#) and [Georgia Tech](#) lead pioneering work in biomedical engineering and infectious disease research, supported by the [Centers for Disease Control and Prevention](#) (CDC), which plays a critical role in global health challenges.

The city's innovation ecosystem is further strengthened by [Science Square](#) and the [Rowen Foundation](#), which are expanding R&D infrastructure with dedicated lab space and research facilities. Atlanta benefits from strong NIH funding, with Emory alone securing over \$485 million in 2023, while state tax credits and grants encourage further investment in research. With a growing emphasis on STEM education and workforce diversity, Atlanta cultivates a steady pipeline of scientific talent. Combined with lower operational costs and access to Hartsfield-Jackson International Airport, the city is positioning itself as a leading destination for research-driven biotech and MedTech innovation.

Pittsburgh (PA)

Pittsburgh is transforming into a player in life sciences innovation, capitalizing on its strengths in artificial intelligence, regenerative medicine, and cell and gene therapy (CGT). The city fosters deep integration of AI and robotics with biological sciences, particularly in biomanufacturing and personalized medicine.

Key institutions such as [Carnegie Mellon University](#) (CMU), the [University of Pittsburgh \(Pitt\)](#), and [UPMC](#) anchor the city's research landscape, with specialized programs in bioengineering

and computational biology. Pittsburgh's focus on advanced therapeutics is reinforced by [BioForge](#), a new CGT production facility, and increased NIH funding, which reached \$675 million in 2022. The city's rapidly growing research infrastructure is further supported by [LifeX Labs](#) and the [Pittsburgh Life Sciences Greenhouse](#), which provide crucial resources for early-stage innovation. While Pittsburgh continues to attract biotech startups, targeted workforce development remains key to sustaining long-term growth.

Chicago (IL)

Chicago is home to a rapidly expanding life sciences research ecosystem, with strengths in genomics, precision medicine, and biomedical technology. The city benefits from its concentration of world-class institutions, including [Northwestern University](#), the [University of Chicago](#), and the [University of Illinois](#), which are driving major advancements in biopharmaceutical research and bioinformatics.

The city's research environment is fueled by strong interdisciplinary collaboration and state-backed incentives such as [the Illinois SBIR Matching Program](#) and the Angel Tax Credit, which encourage biotech R&D. [The Illinois Science & Technology Coalition \(ISTC\)](#) and [MATTER](#), a health-tech accelerator, support translational research and commercialization efforts. Chicago has seen a 76% increase in lab space since 2018, making it an attractive destination for research-intensive startups. With a growing talent base, competitive infrastructure, and a focus on data-driven biomedical advancements, Chicago continues to strengthen its position as an innovation leader.

Providence (RI)

Providence is emerging as a innovation hub in life sciences R&D, driven by a strong academic presence and rising biotech investments. [Brown University](#) is at the forefront of this transformation, expanding research capabilities in bioengineering, public health, and advanced therapeutics. The university's new state-of-the-art life sciences building is expected to accelerate discoveries in neuroscience and regenerative medicine, further integrating research into clinical applications.

The city has experienced a 53% increase in life sciences establishments since 2018, fueled by venture capital investments and state-backed incentives. Providence benefits from its proximity to Boston, offering research institutions and biotech startups access to world-class talent and industry collaborations. With a focus on translational medicine and digital health, Providence is positioning itself as a rising hub for biomedical research and next generation therapeutics.

Orange County (CA)

Orange County has become a leading center for medical technology innovation, with a strong focus on biomedical devices, biopharmaceutical research, and advanced diagnostics. The region's MedTech industry is anchored by companies like [Edwards Lifesciences](#) and [Allergan](#), which are driving advancements in cardiovascular and ophthalmic technologies.

Research institutions, including the [University of California, Irvine](#) (UCI), support the ecosystem with cutting-edge work in bioengineering and regenerative medicine. The region benefits from a high density of R&D talent, fueled by strong industry-academic collaboration. While Orange County's cost of living is high, its expanding lab space, venture capital presence, and proximity to Los Angeles make it a critical hub for medical innovation and translational research. As investments in AI-driven diagnostics and wearable medical technology increase, Orange County continues to be a top destination for R&D-focused life sciences enterprises.

Philadelphia (PA)

Philadelphia has cemented itself as a leader in cell and gene therapy (CGT) innovation, immunotherapy, and precision medicine. The city is home to some of the world's top research institutions, including the [University of Pennsylvania](#), [Drexel University](#), and [Thomas Jefferson University](#), which are driving breakthroughs in biomedical sciences.

Philadelphia benefits from one of the highest levels of NIH funding, with over \$5 billion awarded from 2019 to 2023. Major biotech companies and research centers are expanding R&D facilities, with projects like [Schuylkill Yards](#) and the Navy Yard adding 2.8 million square feet of lab space. The city also offers state-backed incentives, such as [Keystone Opportunity Zones](#) (KOZ), which attract research-driven startups.

With an established talent pipeline – ranking sixth in the U.S. for life sciences talent – and a growing emphasis on biomanufacturing and connected health technologies, Philadelphia continues to be a driving force in next-generation medical research.

Phoenix (AZ)

Phoenix is rapidly establishing itself as a center for biotechnology, medical research, and bioengineering, driven by [Arizona State University](#) (ASU) and the [Translational Genomics Research Institute](#) (TGen). The city is fostering a research-intensive ecosystem, with major developments in computational biology, biomedical imaging, and nanomedicine.


Phoenix offers a business-friendly climate, with state incentives that encourage early-stage research and biotech commercialization. The city is also expanding its lab infrastructure, providing critical research space for startups in biotechnology and medical diagnostics. With lower operational costs than traditional biotech hubs, Phoenix is attracting a growing number of R&D-focused firms, making it an emerging hub for life sciences innovation.

Portland (OR)

Portland is rapidly gaining recognition as a growing center for biotech and life sciences innovation, with a 31% expansion in its life sciences sector since 2018. The city's ecosystem is anchored by [Oregon Health & Science University](#) (OHSU), a player in genomics, oncology, and precision medicine. OHSU's partnership with [Portland State University](#) and major biotech firms has strengthened its position in drug discovery and computational biology.

Portland is also emerging as a hub for biomanufacturing and green biotechnology, integrating sustainable practices into pharmaceutical and biomedical research. New lab developments are addressing the city's growing demand for research space, providing facilities for both established biotech firms and startups. With an emphasis on interdisciplinary research and AI-driven life sciences, Portland is becoming a strong alternative for companies looking to innovate outside traditional biotech markets.

About the Dutch Diplomatic Network in the U.S.



The Dutch diplomatic network in the United States plays a vital role in strengthening economic, scientific, and innovation ties between the Netherlands and the U.S. This network includes the Netherlands Innovation Network, the Netherlands Business Support Offices (NBSO), and Consulates.

The Consulates of the Kingdom of the Netherlands in the U.S. work to strengthen economic ties within all states of the U.S. With Consulates in San Francisco, Atlanta, Miami, Chicago & New York, we try to promote trade and find both smart- and social solutions to our mutual problems. Programs like ScaleNL and various economic missions offer great opportunities for Dutch startups looking for opportunities in the U.S.

The Netherlands Innovation Network is part of the Dutch Ministry of Economic Affairs and is the science and technology arm of the Dutch diplomatic network. With offices in Boston, San Francisco & Washington, we work with startups, companies, and research institutes/universities from the Netherlands and facilitate exploration of innovation opportunities in the U.S.

Netherlands Business Support Offices are the Dutch governmental trade offices outside of the Netherlands. NBSOs support your plans abroad. The NBSOs will help you with exporting, setting up a business abroad or looking for market information or business partners.

The Dutch diplomatic network in the United States has offices in:

Arizona
NBSO-Phoenix
California
Consulate General of the Kingdom of the Netherlands in San Francisco
Netherlands Innovation Network in San Francisco
NBSO-Los Angeles
Florida
Consulate General of the Kingdom of the Netherlands in Miami
Georgia
Consulate General of the Kingdom of the Netherlands in Atlanta
Illinois
Consulate General of the Kingdom of the Netherlands in Chicago
Massachusetts
Netherlands Innovation Network in Boston
New York
Consulate General of the Kingdom of the Netherlands in New York
Texas
NBSO-Houston
Washington, D.C.
Embassy of the Kingdom of the Netherlands in the United States
Netherlands Innovation Network in the United States

These offices closely collaborate with Dutch ministries, industry partners, and regional development agencies to facilitate trade, investment, and knowledge exchange. With its wide geographical coverage and deep sector expertise, the Dutch diplomatic network acts as a bridge for entrepreneurs seeking to scale internationally, ensuring that Dutch innovation is well-represented and effectively positioned in the highly competitive U.S. LSH landscape.

This is a publication of

Netherlands Enterprise Agency
Prinses Beatrixlaan 2
PO Box 93144 | 2509 AC The Hague
T +31 (0) 88 042 42 42
[Contact](#)
www.rvo.nl

This publication was commissioned by the ministry of Foreign Affairs.
© Netherlands Enterprise Agency | December 2025

Publication number: RVO-272-2025/RP-INT

NL Enterprise Agency is a department of the Dutch ministry of Economic Affairs that implements government policy for Agricultural, sustainability, innovation, and international business and cooperation. NL Enterprise Agency is the contact point for businesses, educational institutions and government bodies for information and advice, financing, networking and regulatory matters.

Netherlands Enterprise Agency is part of the ministry of Economic Affairs.